DERMATA THERAPEUTICS, INC. Selling, General and Administrative Expense
DERMATA THERAPEUTICS, INC. (DRMA) reported Selling, General and Administrative Expense of $2.80 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:SellingGeneralAndAdministrativeExpense · last filed 2026-08-11
- DERMATA THERAPEUTICS, INC. selling, general and administrative expense for the quarter ending 2026-06-30 was $2.80M, a 142.53% increase year-over-year.
- DERMATA THERAPEUTICS, INC. selling, general and administrative expense for the quarter ending 2026-03-31 was $1.54M, a 45.72% increase year-over-year.
- DERMATA THERAPEUTICS, INC. selling, general and administrative expense for the quarter ending 2025-12-31 was $1.37M, a 36.31% increase year-over-year.
- DERMATA THERAPEUTICS, INC. selling, general and administrative expense for the quarter ending 2025-09-30 was $1.26M, a 52.41% increase year-over-year.
- DERMATA THERAPEUTICS, INC. selling, general and administrative expense for fiscal 2025 was $4.84M, a 12.39% increase from fiscal 2024.
- DERMATA THERAPEUTICS, INC. selling, general and administrative expense for fiscal 2024 was $4.31M.
| Period end | Selling, General and Administrative Expense 3 month | Selling, General and Administrative Expense 6 month | Selling, General and Administrative Expense 9 month | Selling, General and Administrative Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $2.80M 10-Q · filed 2026-08-11 | $4.34M 10-Q · filed 2026-08-11 | $5.72M derived: sum of 3 quarters · filed 2026-08-11 | $6.97M derived: sum of 4 quarters · filed 2026-08-11 |
| 2026-03-31 | $1.54M 10-Q · filed 2026-05-13 | $2.92M derived: sum of 2 quarters · filed 2026-05-13 | $4.17M derived: sum of 3 quarters · filed 2026-05-13 | $5.33M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-12-31 | $1.37M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-26 | $2.63M derived: sum of 2 quarters · filed 2026-03-26 | $3.78M derived: sum of 3 quarters · filed 2026-08-11 | $4.84M 10-K · filed 2026-03-26 |
| 2025-09-30 | $1.26M 10-Q · filed 2025-11-14 | $2.41M derived: sum of 2 quarters · filed 2026-08-11 | $3.47M 10-Q · filed 2025-11-14 | $4.48M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-06-30 | $1.15M 10-Q · filed 2026-08-11 | $2.21M 10-Q · filed 2026-08-11 | $3.22M derived: sum of 3 quarters · filed 2026-08-11 | $4.05M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-03-31 | $1.06M 10-Q · filed 2026-05-13 | $2.07M derived: sum of 2 quarters · filed 2026-05-13 | $2.89M derived: sum of 3 quarters · filed 2026-05-13 | |
| 2024-12-31 | $1.01M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-26 | $1.83M derived: sum of 2 quarters · filed 2026-03-26 | $4.31M 10-K · filed 2026-03-26 | |
| 2024-09-30 | $824.29K 10-Q · filed 2025-11-14 | $3.30M 10-Q · filed 2025-11-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH) | United States | $0.005B | |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |
| Lakewood-Amedex Biotherapeutics Inc. (LABT) | United States | $0.004B | |
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| 60 DEGREES PHARMACEUTICALS, INC. (SXTP) | United States | $0.004B | -0.59 |
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| ProPhase Labs, Inc. (PRPH) | United States | $0.006B | -0.06 |
| REVELATION BIOSCIENCES, INC. (REVB) | United States | $0.004B | |
| HCW Biologics Inc. (HCWB) | United States | $0.004B | -6.15 |